|
摘要：
|
|
摘要：目的 探讨微小RNA（micro RNA，miRNA）-574-5p、miRNA-106b、高敏甲胎
蛋白异质体（highly sensutive-alpha fetoprotein heterogeneity L3，hs-AFP-L3）水平检测
对早期肝细胞癌（hepatocellular carcinoma，HCC）的诊断价值。方法 选择吉林省肿瘤
医院2020年3月至2022年3月收治的HCC患者186例（HCC组）、肝硬化患者120例（肝
硬化组）、接受体检的健康人员120例（对照组）为研究对象。比较各组血清miRNA-
574-5p、miRNA-106b、hs-AFP-L3 水平，并比较HCC组不同病理特征患者血清miRNA-
574-5p、miRNA-106b、hs-AFP-L3水平，绘制受试者工作特征（receiver operator
characteristic，ROC）曲线分析miRNA-574-5p、miRNA-106b、hs-AFP-L3对早期HCC
的诊断价值。结果 HCC组、肝硬化组和对照组患者血清miRNA-574-5p（1.09 ± 0.33比
0.84 ± 0.27比0.61 ± 0.18）、miRNA-106b（1.22 ± 0.39比0.71 ± 0.22比0.56 ± 0.19）、hsAFP-L3 [（23.08 ± 4.36）μg/L比（2.61 ± 0.79）μg/L比（0.47 ± 0.14）μg/L] 水平差异有
统计学意义，HCC组患者各项指标均显著高于肝硬化组和对照组，肝硬化组患者各项
指标均显著高于对照组（P均＜ 0.05）。HCC肿瘤个数为多发、肿瘤最大径≥ 5 cm、中
晚期、有远处转移、有静脉瘤栓患者血清miRNA-574-5p、miRNA-106b、hs-AFP-L3水
平分别高于单发 [miRNA-574-5p：1.24 ± 0.43比0.83 ± 0.27；miRNA-106b：1.46 ± 0.45比
0.97 ± 0.31；hs-AFP-L3：（25.73 ± 5.21）μg/L比（19.15 ± 4.25）μg/L]、肿瘤最大径＜ 5 cm
[miRNA-574-5p：1.29 ± 0.46比0.82 ± 0.24；miRNA-106b：1.51 ± 0.44比0.95 ± 0.29；
hs-AFP-L3：（26.82 ± 5.03）μg/L比（19.12 ± 3.99）μg/L]、早期[miRNA-574-5p：
1.31 ± 0.44比0.90 ± 0.28；miRNA-106b：1.49 ± 0.51比0.99 ± 0.32；（26.60 ± 4.98）μg/L
比（18.94 ± 4.02）μg/L]、无远处转移 [miRNA-574-5p：1.36 ± 0.46比0.88 ± 0.25；
1.45 ± 0.41比0.96 ± 0.32；hs-AFP-L3：（26.79 ± 5.44）μg/L比（19.04 ± 3.83）μg/L]、无
静脉瘤栓患者 [miRNA-574-5p：1.39 ± 0.43比0.92 ± 0.31；miRNA-106b：1.43 ± 0.39比
1.0 ± 0.34；hs-AFP-L3：（26.41 ± 4.54）μg/L比（20.11 ± 4.01）μg/L]（P ＜ 0.05）；肝
功能Child-Pugh分级A级、B级、C级患者血清miRNA-574-5p（0.85 ± 0.26比1.08 ± 0.37
比1.27 ± 0.40）、miRNA-106b（0.92 ± 0.29比1.15 ± 0.35比1.41 ± 0.38）、hs-AFP-L3
[（18.69 ± 3.72）μg/L比（23.17 ± 4.88）μg/L比（26.45 ± 5.32）μg/L] 含量逐渐增加（P均＜
0.05）。miRNA-574-5p、miRNA-106b、hs-AFP-L3联合检测诊断早期HCC的曲线下面积
为0.919（95%CI为0.873～0.980），敏感度和特异度分别为0.882、0.901。结论 miRNA-
574-5p、miRNA-106b、hs-AFP-L3联合检测对早期HCC的诊断具有较高的临床价值。
|
|
Abstract: Objective To investigate the diagnostic value of micro RNA (miRNA)-574-5p,
miRNA-106b and high-sensitivity alpha fetoprotein heterogeneity (hs-AFP-L3) on early
hepatocellular carcinoma (HCC). Methods Total of 186 patients with HCC (HCC group), 120
patients with liver cirrhosis (liver cirrhosis group) and 120 healthy controls (control group)
addmitted to Jilin Cancer Hospital from March, 2020 to March, 2022 were selected. The
serum miRNA-574-5p, miRNA-106b and hs-AFP-L3 levels of patients in each group were
compared, and the above indexes in patients with different pathological characteristics of
HCC group were also compared. The receiver operating characteristic (ROC) curve was used
to analyze the diagnostic value of miRNA-574-5p, miRNA-106b and hs-AFP-L3 on early
HCC. Results The differences of serum miRNA-574-5p (1.09 ± 0.33 vs. 0.84 ± 0.27 vs. 0.61 ± 0.18),
miRNA-106b (1.22 ± 0.39 vs. 0.71 ± 0.22 vs. 0.56 ± 0.19) and hs-AFP-L3 [(23.08 ± 4.36) μg/L vs.
(2.61 ± 0.79) μg/L vs. (0.47 ± 0.14) μg/L] levels of patients in three groups were statistically
significant, the above indexes of patients in HCC group were significantly higher than those
of liver cirrhosis group and control group, and the above indexes of patients in liver cirrhosis
group were significantly higher than those of control group (all P ＜ 0.05). Serum miRNA-
574-5p, miRNA-106b, hs-AFP-L3 levels in patients with multiple lesion, maximum tumor
diameter ≥ 5 cm, distant metastasis and venous tumor thrombus were significantly higher
than those of patients with single lesion [miRNA-574-5p: 1.24 ± 0.43 vs. 0.83 ± 0.27; miRNA-
106b: 1.46 ± 0.45 vs. 0.97 ± 0.31; hs-AFP-L3: (25.73 ± 5.21) μg/L vs. (19.15 ± 4.25) μg/L],
maximum tumor diameter ＜ 5 cm [miRNA-574-5p: 1.29 ± 0.46 vs.0.82 ± 0.24; miRNA-106b:
1.51 ± 0.44 vs. 0.95 ± 0.29; hs-AFP-L3: (26.82 ± 5.03) μg/L vs. (19.12 ± 3.99) μg/L], middle and
late stage [miRNA-574-5p: 1.31 ± 0.44 vs. 0.90 ± 0.28; miRNA-106b: 1.49 ± 0.51 vs. 0.99 ± 0.32;
hs-AFP-L3: (26.60 ± 4.98) μg/L vs. (18.94 ± 4.02) μg/L], no distant metastasis [miRNA-574-
5p: 1.36 ± 0.46 vs. 0.88 ± 0.25; miRNA-106b: 1.45 ± 0.41 vs. 0.96 ± 0.32; hs-AFP-L3: (26.79 ±
5.44) μg/L vs. (19.04 ± 3.83) μg/L] and no venous tumor thrombus [miRNA-574-5p: 1.39 ± 0.43
vs. 0.92 ± 0.31; miRNA-106b: 1.43 ± 0.39 vs. 1.0 ± 0.34; hs-AFP-L3: (26.41 ± 4.54) μg/L vs.
(20.11 ± 4.01) μg/L] (all P ＜ 0.05). The serum levels of miRNA-574-5p (0.85 ± 0.26 vs. 1.08 ±
0.37 vs. 1.27 ± 0.40), miRNA-106b (0.92 ± 0.29 vs. 1.15 ± 0.35 vs. 1.41 ± 0.38), hs-AFP-L3
[(18.69 ± 3.72) μg/L vs. (23.17 ± 4.88) μg/L vs. (26.45 ± 5.32) μg/L] gradually increased in
patients with Child-Pugh grade A, B and C (all P ＜ 0.05). The area under the ROC curve of
miRNA-574-5p, miRNA-106b and hs-AFP-L3 combined detection for the diagnosis of early
HCC was 0.919 (95% CI 0.873～0.980), and the sensitivity and specificity were 0.882 and
0.901, respectively. Conclusions The combined detection of miRNA-574-5p, miRNA-106b
and hs-AFP-L3 had a high clinical value for the diagnosis of early HCC.
|
|
基金项目：
|
|
|
|
作者简介：
|
|
|
|
参考文献：
|
|
|
|
服务与反馈：
|
|
【文章下载】【加入收藏】
|
|
|
|